TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04519996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US Internal Jugular Vein Collapsibility Index measurment
Description: Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A curvilinear USG probe for IVC imaging (1-5 MHz, 21 mm).~The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility. Care will be taken not to compress or obliterate the vein by applying minimal pressure. When the whole circumference of the vein will be visible the measurements were done. The recordings will be done for four respiratory cycles. The maximum, minimum AP diameters, and cross-sectional area will be estimated and, from this, corresponding CI will be derived (Maximum diameter or cross-sectional area (CSA)-minimum diameter or CSA/maximum diameter or CSA) ×100%. All the above measurements will be repeated with the head end of patients elevated to 30° position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US Inferior Vena Cava Collapsibility Index measurment
Description: Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A linear vascular transuder for IJV imaging (7-13 MHz, 38 mm) will be used.~The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration. The maximum (IVCD) and minimum (IVCD) internal anteroposterior (AP) diameters of the IVC at the end of expiration and inspiration respectively over the same respiratory cycle will be measured. The IVCCI is derived from the equation, IVCCI= (IVCD max -IVCD min)/IVCD max × 100.
Study: NCT03370770

Intervention type: DRUG
Intervention: Afatinib
Description: GILOTRIF, GIOTRIF, XOVOLTIB

Intervention type: DRUG
Intervention: Osimertinib
Description: on T790M resistance mutation was developed
Study: NCT03135145

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lite Run Gait Trainer
Description: Lite Run is a new system for the treatment of patients with gait and balance difficulties that uses differential air pressure inside a lower body suit to reduce up to 50 percent of a patient's body weight. The suit is similar to a pair of pants in appearance and is as easy to don and doff as a pair of pants. The suit uses technology like astronaut spacesuits to achieve comfort and flexibility while providing a unique unweighting effect that facilitates patient ambulation from sitting through taking steps. The suit is used in conjunction with the Lite Run Gait Trainer, which provides air pressure to the suit and support for the patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Treatments
Description: The usual clinical treatments (standard of care treatments) will be used to assist patients in weightbearing and walking.
Study: NCT00179959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite (bleach) baths
Description: Sodium hypochlorite (bleach) baths twice weekly for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water baths twice weekly for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum Ointment
Description: Intranasal petrolatum ointment twice daily for five days
Study: NCT00793767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: bolus of 400 IU/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Description: i.v
Study: NCT01552681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept
Description: Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
Study: NCT04363333

Intervention type: DIAGNOSTIC_TEST
Intervention: Home Sleep Apnea Testing or In-hospital Polysomnography
Description: Home Sleep Apnea Testing or In-hospital Polysomnography will be conducted 4 to 6 months after the Covid-19 diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Home Sleep Apnea Testing or In-hospital Polysomnography
Description: Home Sleep Apnea Testing or In-hospital Polysomnography will be conducted 4 to 6 months after the Covid-19 diagnosis
Study: NCT00627237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Start
Description: Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waitlist
Description: Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
Study: NCT03871894

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)
Description: Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)
Description: Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard and fixed nutritional intervention till patient in ICU
Description: Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard and fixed nutritional intervention till patient in ICU
Description: Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator
Study: NCT02800460

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fMRI-3T
Description: fMRI-3T will be performed during the visit 1: day of anesthesia consultation (this fMRI-3T will last approximately one hour)
Study: NCT00814385

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (Single prime, single boost)
Description: Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (Single prime, single boost)
Description: Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (single prime, single boost)
Description: Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (single prime, single boost)
Description: Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (Double prime, single boost)
Description: Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (double prime, single boost)
Description: Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (double prime, single boost)
Description: Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (double prime, single boost)
Description: Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (No prime, single boost)
Description: No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
Study: NCT00253708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: massage therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pain therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT01029405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728
Description: Ointment B, 2% or 0.5% applied once or twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728
Description: Ointment B, 2% or 0.5% applied once or twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728
Description: Ointment B, 2% or 0.5% applied once or twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728
Description: Ointment B, 2% or 0.5% applied once or twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ointment B Vehicle applied once or twice daily
Study: NCT03976180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stadard low-flow oxygen
Description: In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNO with low FiO2 (21%-30%)
Description: HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
Study: NCT02170311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-213
Study: NCT02318758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C
Description: sustained release oral treprostinil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C
Description: sustained release oral treprostinil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C
Description: sustained release oral treprostinil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C
Description: sustained release oral treprostinil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ethanol
Description: Absolut 100 vodka

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ethanol
Description: Absolut 100 vodka

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ethanol
Description: Absolut 100 vodka
Study: NCT01350089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (without alcohol, caffeine, energy drink)
Description: (carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator 1 (with alcohol; without caffeine and energy drink)
Description: Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator 2 (with alcohol and caffeine; without energy drink)
Description: Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 3 (with alcohol and energy drink)
Description: Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
Study: NCT01773655

Intervention type: OTHER
Intervention: tumor specimens
Description: All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).~Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome.
Study: NCT02750202

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent HPV vaccine
Description: Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
Study: NCT01596257

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic hematopoietic stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic hematopoietic stem cell transplant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Study: NCT04049019

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine collection through a collecting device (Uridome®) for maximum 1 week
Description: The child will collect:~* Urine at bedtime before a wet and a dry night.~* Urine during a wet night through a collecting device.~* First morning voided volume following both a wet and a dry night.
Study: NCT02170311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-213
Study: NCT01950637

Intervention type: BEHAVIORAL
Intervention: No treatment given
Description: Completion of 90-item online questionnaire.
Study: NCT03976180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNO with intermediate FiO2 (50%)
Description: In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNO with high FiO2 (100%)
Description: In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
Study: NCT03253471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-611
Description: AL-611 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Match AL-611
Study: NCT02643056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: IV administration every 2 weeks
Study: NCT01073371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: 1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: 1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: 1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
Study: NCT02222025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury Prevention Programme
Description: The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
Study: NCT03152006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACT
Description: Coordinated, graduated transition which includes an early introduction to the adult clinician during the PAPA pre-transfer period, a peer-facilitated organized support group aimed at improving transition readiness and addressing critical psychosocial skills including self-efficacy and locus of control and a case management team including a patient advocate who coordinates the transfer between pediatric and adult care teams.
Study: NCT02822547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Patients will receive Peginterferon alfa-2a according to the standard medical practice
Study: NCT00704275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporin eye drop
Description: bid dosage for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% cyclosporin eye drop
Description: bid dosage for 4 months
Study: NCT01014923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen driving intervention
Description: Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
Study: NCT03373227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus
Description: Patients will take once daily Envarsus
Study: NCT02660840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg Flupentixol film-coated tablet (test treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg Flupentixol film-coated tablet (test treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg Flupentixol film-coated tablet (test treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg Flupentixol film-coated tablet (test treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Flupentixol film-coated tablet (test treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Flupentixol film-coated tablet (test treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg Flupentixol coated tablet (reference treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg Flupentixol coated tablet (reference treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg Flupentixol coated tablet (reference treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg Flupentixol coated tablet (reference treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Flupentixol coated tablet (reference treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Flupentixol coated tablet (reference treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study: NCT02539056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chondron Implantation
Description: In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.